Managers

Nauta Capital wraps up new fund

Nauta Capital, a pan-European venture firm, has closed its new fund at 55 million euros. The Sidecar Fund will invest in early-stage tech companies. The fund's investors include British Patient Capital, the European Investment Fund, the ICF and the ICO.

Blood test developer Inanovate lands $3.1 mln Series C

South Dakota and North Carolina-based Inanovate Inc., a developer of blood tests for cancer and autoimmune diseases, has secured $3.1 million in Series C financing. South Dakota Equity Partners led the round.

New Era raises $60 mln for inaugural fund

New Era Capital Partners, a Tel Aviv-based venture firm, has closed its debut fund at $60 million. The fund will invest in Israeli social impact companies.

Equal Ventures is seeking $40 mln towards its first fund

Ripple’s bid to disrupt the payments sector

Andreessen Horowitz files to register as an investment adviser

Agtech focused Yield Lab raises over $12 mln towards a $50 mln fund

Hyde Park Venture Partners to raise venture-capital fund

Hyde Park Venture Partners has set out to raise a third venture-capital fund, according to a filing with the SEC.

Fusion Pharmaceuticals racks up $105 mln Series B

Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company, has raised $105 million in Series B financing. Varian and OrbiMed led the round with participation from other investors that included Perceptive Advisors, Pivotal bioVenture Partners, Rock Springs Capital, Healthcap, Adams Street Partners, Johnson & Johnson Innovation – JJDC Inc, TPG Biotech, Seroba Life Sciences, Genesys Capital and FACIT. In conjunction with the funding, Deepak Khuntia, senior vice president and chief medical officer at Varian, Chau Q. Khuong, a partner at OrbiMed and Heather Preston, a managing director at Pivotal bioVenture Partners, will join Fusion’s board of directors.

Belgian biotherapeutics firm AgomAb inks Series A funding

AgomAb, a Belgian biotherapeutics company, has secured 21 million euros in Series A funding. V-Bio Ventures and Advent France Biotechnology led the round with participation from Boehringer Ingelheim Venture Fund, Omnes and Pontifax.